# A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults

> **NCT05061563** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 14 (actual)

## Conditions studied

- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Hot Flashes

## Interventions

- **DRUG:** Elinzanetant (BAY3427080)
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT05061563
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-30
- **Primary completion:** 2021-12-09
- **Final completion:** 2022-02-23
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05061563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05061563, "A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05061563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*